KASID
Current Issue Volume 23(2); April 2025
Intestinal Research
Latest Issue: Volume 23 Issue 2
Editor-in-Chief: Toshifumi Hibi
Print ISSN: 1598-9100
Online ISSN: 2288-1956
Online ISSN: 2288-1956
Frequency: Quarterly
Impact Factor: 3.4
Gastroenterology & Hepatology - Q2 (44/143)
Impact Factor: 3.4
Gastroenterology & Hepatology - Q2 (44/143)
, Ye-Jee Kim
, Kei Moriya
- MOST CITED
-
- Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis43
- Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease35
- Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease25
- Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer24
- MOST VIEWED
-
- Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease11,998
- Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis11,757
- Use of device-assisted enteroscopy in small bowel disease: an expert consensus statement by the Korean Association for the Study of Intestinal Diseases9,644
- Korean Guidelines for Postpolypectomy Colonoscopic Surveillance: 2022 revised edition9,371
- AHEAD OF PRINT
-
- Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China
- Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India
- Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease
- The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study
